Optimizing palliative treatment of metastatic colorectal cancer in the era of biologic therapy

ONCOLOGY

Volumn 21, Issue 5, 2007, Pages 553-566

  Grothey, Axel ^a   Marshall, John L ^b  

^a Mayo Clinic   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; ERLOTINIB; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; UNCLASSIFIED DRUG; VATALANIB; VECTIBIX;

CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DRUG ACTIVITY; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HAND FOOT SYNDROME; HEALTH STATUS; HUMAN; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PALLIATIVE THERAPY; PARESTHESIA; PATIENT CARE; PHYSICAL PERFORMANCE; REVIEW; TREATMENT DURATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CLINICAL TRIALS; COLORECTAL NEOPLASMS; FLUOROURACIL; HUMANS; LEUCOVORIN; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; PALLIATIVE CARE;

EID: 34248165963     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Douillard JY, Cunningham D, Roth AD, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 355:1041-1047, 2000 (erratum in Lancet 355:1372, 2000).
2. Kabbinavar FF, Hambleton J, Mass RD, et al: Combined analysis of efficacy: The addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 23:3706-3712, 2005.
3. de Gramont A, Figer A, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938-2947, 2000.
4. Grothey A, Deschler B, Kroening H, et al: Phase III study of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (Mayo) vs weekly high-dose 24h 5-FU infusion/ FA + oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer (ACRC) (abstract 512). Proc Am Soc Clin Oncol 20:129a, 2002.
5. Kohne CH, Wils J, Lorenz M, et al: Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European Organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952. J Clin Oncol 21:3721-2728, 2003.
6. Saltz LB, Cox JV, Blanke C, et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343:905-914, 2000.
7. Kohne C, de Greve J, Bokemeyer C, et al: Capecitabine plus irinotecan versus 5-FU/FA/irinotecan +/- celecoxib in first line treatment of metastatic colorectal cancer. Safety results of the prospective multicenter EORTC phase III study 40015 (abstract 3525). J Clin Oncol 23(16S):252s, 2005.
8. Giacchetti S, Perpoint B, Zidani R, et al: Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18:136-147, 2000.
9. Goldberg RM, Sargent DJ, Morton RF, et al: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23-30, 2004.
10. Tournigand C, Andre T, Achille E, et al: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 22:229-237, 2004.
11. Colucci G, Gebbia V, Paoletti G, et al: Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer. A multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 23:4866-4875, 2005.
12. Grothey A, Sargent D, Goldberg RM, et al: Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22:1209-1214, 2004.
13. Grothey A, Sargent D: Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J Clin Oncol 23:9441-9442, 2005.
14. Hoff PM, Ansari R, Batist G, et al: Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study. J Clin Oncol 19:2282-2292, 2001.
15. Cassidy J, Twelves C, Van Cutsem E, et al: First-line oral capecitabine therapy in metastatic colorectal cancer: A favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 13:566-575, 2002.
16. Kubicka S, Arkenau H, Grothey A, et al: Randomized trial of infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) as first line treatment of metastatic colorectal carcinoma (MCRC): final results of the safety and efficacy analysis (abstract 277). Presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium. San Francisco; January 26-28, 2006.
17. Cassidy J, Clarke S, Diaz Rubio E, et al: First efficacy and safety results from XELOX-1/NO16966, a randomised 2 x 2 factorial phase III trial of XELOX vs. FOLFOX4 + bevacizumab or placebo in first-line metastatic colorectal cancer (MCRC) (abstract LBA3). Ann Oncol 17(suppl 9), 2006.
18. Jordan K, Kellner O, Kegel T, et al: Phase II trial of capecitabine/irinotecan and capecitabine/oxaliplatin in advanced gastrointestinal cancers. Clin Colorectal Cancer 4:56-50, 2004.
19. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004.
20. Hurwitz H, Fehrenbacher L, Hainsworth J, et al: Bevacizumab in combination with fluorouracil and leucovorin: An active regimen for first-line metastatic colorectal cancer. J Clin Oncol 23:3502-3508, 2005.
21. Hochster HS, Hart LL, Ramanathan RK, et al: Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: Final analysis of the TREE study (abstract 3510). J Clin Oncol 24(18S):148s, 2006.
22. Fuchs CS, Marshall J, Mitchell EP, et al: Updated results of BICC-C study comparing first-line irinotecan/fluoropymidine combinations ± celecoxib in mCRC: Clinical data cut-off September 1, 2006 (abstract 276). Presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium. Orlando, Fla; January 19-21, 2007.
23. Giantonio BJ, Catalano PJ, Meropol NJ, et al: High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200 (abstract 2). J Clin Oncol 23(16S):1s, 2005.
24. Cunningham D, Humblet Y, Siena S, et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337-345, 2004.
25. Saltz LB, Lenz H-J, Hochster H, et al: Randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer (abstract 3508). J Clin Oncol 23(16S):248s, 2005.
26. Peeters M, Van Cutsem E, Siena S, et al: A phase 3, multicenter, randomized controlled trial (RCT) of panitumumab plus best supportive care (BSC) vs BSC alone in patients (pts) with metastatic colorectal cancer (mCRC) (abstract CP-1). Presented at the 97th Annual Meeting of the American Association for Cancer Research; Washington, DC; April 1-4 2006.
27. Green EM, Sargent DJ, Goldberg RM, et al: Detailed analysis of oxaliplatin-associated neurotoxicity in Intergroup trial N9741 (abstract 264O). Ann Oncol 15(suppl 3):70, 2004.
28. Tournigand C, Cervantes A, Figer A, et al: OPTIMOX1: A randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer - a GERCOR study. J Clin Oncol 24:394-400, 2006.
29. Maindrault-Goebel F, Lledo G, Chibaudel B, et al: OPTIMOX2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC). A GERCOR study (abstract 3504). J Clin Oncol 24(18S):147s, 2006.
30. National Institutes of Health: CONCEPT: Comparison of oxaliplatin versus conventional methods with calcium/magnesium in first-line metastatic colorectal cancer. Available at: www.clinicaltrials.gov. ClinicalTrials.gov identifier: NCT00129870. Updated November 14, 2006. Accessed March 8, 2007.
31. National Institutes of Health: Combination chemotherapy and bevacizumab with or without erlotinib in treating patients with metastatic colorectal cancer that cannot be removed by surgery. Available at www.clinicaltrials.gov. ClinicalTrials.gov identifier: NCT00265824. Updated February 20, 2007. Accessed March 8, 2007.
32. National Institutes of Health: A study to compare two Avastin-based treatment regimens for the treatment of metastatic colorectal cancer. Available at www.clinicaltrials.gov. ClinicalTrials.gov identifier: NCT00114946. Updated May 26, 2006. Accessed March 8, 2007.
33. National Institutes of Health: Cetuximab and/or bevacizumab and combination chemotherapy in treating patients with locally advanced or metastatic colorectal cancer. Available at: www.clinicaltrials.gov. ClinicalTrials.gov identifier: NCT00265850. Updated March 5, 2007. Accessed March 8, 2007.
34. National Institutes of Health: PACCE: Panitumumab Advanced Colorectal Cancer Evaluation study. Available at www.clinicaltrials.gov. ClinicalTrials.gov identifier: NCT00115765. Updated February 15, 2007. Accessed March 8, 2007.
35. D' Andre S, Sargent DJ, Cha SS, et al: 5-Fluorouracil-based chemotherapy for advanced colorectal cancer in elderly patients: A North Central Cancer Treatment Group study. Clin Colorectal Cancer 4:325-331, 2005.
36. Mor V, Masterson-Allen S, Goldberg RJ, et al: Relationship between age at diagnosis and treatments received by cancer patients. J Am Geriatr Soc 33:585-589, 1985.
37. Greenfield S, Blanco DM, Elashoff RM, et al: Patterns of care related to age of breast cancer patients. JAMA 257:2766-2770, 1987.
38. Goldberg RM, Sargent D, Bleiberg H, et al: A pooled safety and efficacy analysis of the FOLFOX4 regimen (bi-monthly oxaliplatin plus fluorouracil/leucovorin) in elderly compared to younger patients with colorectal cancer (abstract 228). Presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium. San Francisco; January 26-28, 2006.
39. de Gramont A, Cervantes A, Andre T, et al: OPTIMOX study: FOLFOX 7/LV5FU2 compared to FOLFOX 4 in patients with advanced colorectal cancer (abstract 3525). Proc Am Soc Clin Oncol 23:251, 2004
40. Figer A, Perez N, Carola E, et al: 5-Fluorouracil, folinic acid and oxaliplatin (FOLFOX) in very old patients with metastatic colorectal cancer (abstract 3571). Proc Am Soc Clin Oncol 23:263, 2004.
41. Fyfe GA, Hurwitz H, Fehrenbacher L, et al: Bevacizumab plus irinotecan/5-FU/leucovorin for treatment of metastatic colorectal cancer results in survival benefit in all pre-specified patient subgroups (abstract 3617). Proc Am Soc Clin Oncol 23:274, 2004.
42. Skillings JR, Johnson DH, Miller K, et al: Arterial thromboembolic events (ATEs) in a pooled analysis of 5 randomized, controlled trials (RCTs) of bevacizumab (BV) with chemotherapy (abstract 3019). J Clin Oncol 23(16S):196s, 2005.
43. Kohne CH, Folprecht G: Current perspectives in the treatment of metastatic colorectal cancer. Ann Oncol 15(suppl 4):iv43-53, 2004.
44. Kabbinavar FF, Schulz J, McCleod M, et al: Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: Results of a randomized phase II trial. J Clin Oncol 23:3697-3705, 2005.
45. Jain RK: Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 307:58-62, 2005.
46. Mass RD, Sarkar S, Holden SN, et al: Clinical benefit from bevacizumab (BV) in responding (R) and non-responding (NR) patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol 23(16 suppl):249s, 2005.
47. Grothey A, Sargent D: Randomized study of sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (ACC), an interim safety analysis: A Dutch Colorectal Cancer Group (DCCG) phase III study (abstract 282). Presented at the 42nd Annual Meeting of the American Society of Clinical Oncology; Atlanta; June 2-6, 2006.
48. National Comprehensive Cancer Network (NCCN): Clinical Practice Guidelines in Oncology. Colon Cancer v.1.2005.
49. Folprecht G, Grothey A, Alberts S, et al: Neoadjuvant treatment of unresectable colorectal liver metastases: Correlation between tumour response and resection rates. Ann Oncol 16:1311-1319, 2005.